JP2013522287A - 血清群b髄膜炎菌のためのアジュバント添加ワクチン - Google Patents

血清群b髄膜炎菌のためのアジュバント添加ワクチン Download PDF

Info

Publication number
JP2013522287A
JP2013522287A JP2012557654A JP2012557654A JP2013522287A JP 2013522287 A JP2013522287 A JP 2013522287A JP 2012557654 A JP2012557654 A JP 2012557654A JP 2012557654 A JP2012557654 A JP 2012557654A JP 2013522287 A JP2013522287 A JP 2013522287A
Authority
JP
Japan
Prior art keywords
antigen
immunogenic composition
serogroup
antigens
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522287A5 (enExample
Inventor
ミケーレ パッラオロ,
デレク オハーガン,
リーノ ラプオーリ,
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013522287A publication Critical patent/JP2013522287A/ja
Publication of JP2013522287A5 publication Critical patent/JP2013522287A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2012557654A 2010-03-18 2011-03-18 血清群b髄膜炎菌のためのアジュバント添加ワクチン Pending JP2013522287A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31533610P 2010-03-18 2010-03-18
US61/315,336 2010-03-18
US31757210P 2010-03-25 2010-03-25
US61/317,572 2010-03-25
PCT/IB2011/051148 WO2012020326A1 (en) 2010-03-18 2011-03-18 Adjuvanted vaccines for serogroup b meningococcus

Publications (2)

Publication Number Publication Date
JP2013522287A true JP2013522287A (ja) 2013-06-13
JP2013522287A5 JP2013522287A5 (enExample) 2014-02-20

Family

ID=44512325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557654A Pending JP2013522287A (ja) 2010-03-18 2011-03-18 血清群b髄膜炎菌のためのアジュバント添加ワクチン

Country Status (9)

Country Link
US (1) US20130071422A1 (enExample)
EP (1) EP2547357A1 (enExample)
JP (1) JP2013522287A (enExample)
CN (1) CN102802662A (enExample)
AU (1) AU2011288203A1 (enExample)
BR (1) BR112012022896A2 (enExample)
CA (1) CA2793510A1 (enExample)
MX (1) MX2012010609A (enExample)
WO (1) WO2012020326A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534712A (ja) * 2014-09-26 2017-11-24 ザ ケマーズ カンパニー エフシー リミテッド ライアビリティ カンパニー 部分フッ素化ウレタン系コーティング

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
IN2012MU00206A (enExample) * 2012-01-20 2013-08-09
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR112015005056A2 (pt) * 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
AU2013320313B2 (en) * 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN104707134A (zh) * 2015-03-27 2015-06-17 成都欧林生物科技股份有限公司 一种无细胞百日破联合疫苗及其制备方法
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
PL240667B1 (pl) * 2018-03-26 2022-05-16 Gdanski Univ Medyczny Peptyd, będący fragmentem płytkopochodnego czynnika wzrostu do zastosowania jako środek leczniczy do podania na skórę w zaburzeniach naskórka do stymulacji odbudowy naskórka
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500540A (ja) * 1996-08-27 2001-01-16 カイロン コーポレイション Neisseria meningitidis血清型B複合糖質およびその使用法
JP2006516608A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 複数の髄膜炎菌血清群に対する注射可能ワクチン
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JP3626996B2 (ja) 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム B型肝炎表面抗原および他の抗原からなる複合ワクチン
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
NZ311000A (en) 1995-06-07 1999-04-29 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AU7701098A (en) 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
DE69738472T2 (de) 1997-08-21 2009-01-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
PT1127137E (pt) 1998-11-03 2007-12-28 Staat Nl Verteg Door Min Welzi Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
DE60325696D1 (de) 2002-02-22 2009-02-26 Ca Nat Research Council Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500540A (ja) * 1996-08-27 2001-01-16 カイロン コーポレイション Neisseria meningitidis血清型B複合糖質およびその使用法
JP2006516608A (ja) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ 複数の髄膜炎菌血清群に対する注射可能ワクチン
WO2009104097A2 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014052174; Proc. Natl. Acad. Sci. USA, 2006, Vol.103, No.29, pp.10834-10839 *
JPN6014052175; Scand. J. Immunol., 2009, Vol.69, No.3, pp.194-202 *
JPN6014052176; J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci., 2005, Vol.822, No.1-2, pp.263-270 *
JPN6014052177; Vaccine, 2006, Vol.24, No.26, pp.5461-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534712A (ja) * 2014-09-26 2017-11-24 ザ ケマーズ カンパニー エフシー リミテッド ライアビリティ カンパニー 部分フッ素化ウレタン系コーティング

Also Published As

Publication number Publication date
BR112012022896A2 (pt) 2018-03-27
MX2012010609A (es) 2012-10-03
US20130071422A1 (en) 2013-03-21
EP2547357A1 (en) 2013-01-23
CA2793510A1 (en) 2012-02-16
WO2012020326A1 (en) 2012-02-16
AU2011288203A1 (en) 2012-08-23
CN102802662A (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
US20130071422A1 (en) Adjuvanted vaccines for serogroup b meningococcus
JP5925736B2 (ja) 髄膜炎菌ワクチン処方物
JP6191082B2 (ja) より低用量の抗原および/またはアジュバントを有する混合ワクチン
JP5637848B2 (ja) 髄膜炎ワクチンの製剤化
JP6324961B2 (ja) 血清群b髄膜炎菌とd/t/pとの組み合わせワクチン
JP5806204B2 (ja) 肺炎球菌血清型14の糖を含む組み合わせ
JP2010529103A5 (enExample)
AU2009289059A1 (en) Outer membrane vesicle prime - protein boost vaccine
CA2894260A1 (en) Conjugates for protecting against diphtheria and/or tetanus
KR20150065878A (ko) 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
JP2016034980A (ja) アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
AU2013202593A1 (en) Adjuvanted vaccines for serogroup B meningococcus
AU2013204315B2 (en) Meningococcal vaccine formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150519